Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2021 · 10-Q
Revenue$705.00K$705.00K+124.5% vs Q2 2020 Net Income-$8.13M-$8.13MN/M vs Q2 2020 EPS Diluted-$0.04-$0.04N/M vs Q2 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Operating Cash Flowderived-$8,419,000N/M Free Cash Flowderived-$9,413,000N/M Margins · derivedGross margin70.1%
Operating margin-1070.2%−65.4 pt vs Q2 2020
Net margin-1153.0%+45.0 pt vs Q2 2020
ended Dec 31, 2020 · filed Feb 16, 2021 · 47 d after period end